hydralazine and cyclosporine

hydralazine has been researched along with cyclosporine in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (25.00)18.2507
2000's5 (41.67)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Andoh, TF; Bennett, WM; Burdmann, EA; Coffman, TM; Connors, BA; Evan, A; Lindsley, J; Nast, CC1
Albers, N; Beier, C; Bohnhorst, B; Bökenkamp, A; Brodehl, J; Offner, G1
Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE1
Aoyama, T; Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kawasaki, M; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H1

Reviews

1 review(s) available for hydralazine and cyclosporine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

11 other study(ies) available for hydralazine and cyclosporine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.
    The American journal of physiology, 1995, Volume: 269, Issue:4 Pt 2

    Topics: Animals; Biphenyl Compounds; Blood Pressure; Cyclosporine; Enalapril; Furosemide; Hydralazine; Imidazoles; Kidney; Kidney Diseases; Losartan; Male; Microscopy, Electron, Scanning; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Tetrazoles

1995
Nifedipine aggravates cyclosporine A-induced gingival hyperplasia.
    Pediatric nephrology (Berlin, Germany), 1994, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Gingival Hyperplasia; Graft Rejection; Humans; Hydralazine; Hypertension; Kidney Transplantation; Male; Nifedipine

1994
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
    Kidney international, 1998, Volume: 53, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Arginine; Biotin; Cyclosporine; Deoxyuracil Nucleotides; DNA Fragmentation; Enzyme Inhibitors; Fibrosis; Hydralazine; Immunosuppressive Agents; Ischemia; Kidney; Losartan; Macrophages; Male; Nephritis, Interstitial; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Staining and Labeling

1998
Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:4

    Topics: Amlodipine; Animals; Apoptosis; bcl-Associated Death Protein; Calcineurin; Calcineurin Inhibitors; Calcium; Calcium Channel Blockers; Calcium Channels; Cells, Cultured; Coronary Vessels; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; fas Receptor; Granulation Tissue; Hydralazine; Ligation; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Phosphorylation; Research Design; Tacrolimus; Time Factors; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2007